Biotech's Favorite New Trick for Pretending Everything Is Fine
Biotech startups are dodging down rounds by reopening old funding rounds instead of raising new ones. It's clever financial engineering, but the strategy reveals just how much stress still lurks beneath the surface of private biotech markets.
The Valuation Game Nobody Wants to Lose
Imagine you bought your house at the peak of the market. Now you need to refinance, but the appraisal would come in way lower. So instead of getting a new mortgage, you just… extend the old one and pretend the price never changed.
That's basically what a growing number of biotech startups are doing with their fundraising. Rather than raise a fresh round of capital (which would force them to put a new price tag on the company), they're reopening their last round and tacking on more money at the same terms. It's called a funding extension, and it has quietly become one of the most popular moves in biotech finance.
The reason is simple: nobody wants a down round.
What Exactly Is a Funding Extension?
In a traditional financing, a startup negotiates a new valuation and sells shares at a new price. Series A, then Series B, then Series C; each one is supposed to be higher than the last, signaling that the company is making progress.
A funding extension skips all that. Instead of launching a new round, the company reopens its previous one. Same share class. Same price. Same terms (mostly). Think of it like ordering a second helping at a buffet instead of going to a different restaurant. You get more food without anyone questioning your taste.
The alternative is ugly. A down round means raising money at a lower valuation than last time, which sends a flashing red signal to employees, future investors, and the broader market. It also hammers existing shareholders with extra dilution through anti-dilution protections that kick in automatically. Extensions let companies dodge all of that.
The Numbers Tell the Story
A 12-month look at biotech financings through May 2026 paints a striking picture. Of 24 disclosed equity rounds, 16 were follow-ons, not fresh first-time financings. Investors are reinforcing companies they already back rather than writing new checks to new names.
The capital is also concentrating in fewer hands. Twenty-two of those 24 rounds were above $50 million, with a . That's not a broad-based funding market; it's a velvet-rope club where the bouncer checks your clinical data before letting you in.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
median round size of $92 million
Meanwhile, deal counts have cratered. U.S. VC-backed biotech rounds fell 25% year-over-year in 2025 to just 237, the lowest in at least five years. Total transaction value dropped to $13.3 billion. Fewer companies are getting funded, period. The ones that do get funded are raising bigger checks, often through extensions of rounds they've already closed.
Why the Public Market Rally Hasn't Fixed This
If you've been watching biotech stocks, you might think everything is rosy. The XBI (a popular biotech index) climbed roughly 35% in 2025 and is up about 95-110% from its April 2025 trough. Big Pharma has been on a buying spree, with over $100 billion in M&A deal value. The IPO window is creaking open again.
So why are private companies still scrambling for oxygen?
Because the public rally hasn't fully trickled down. Many private biotechs raised their last rounds during the 2020-2021 boom, when valuations were, to put it politely, ambitious. A preclinical company that raised its Series B at a billion-dollar valuation three years ago can't exactly walk into a new round today and expect that number to hold up. Public comps have reset. Investor expectations have reset. But those old valuations are still sitting on cap tables like vintage wine that turned to vinegar.
The IPO window illustrates the disconnect perfectly. Only about 10 U.S. biotech IPOs happened in 2025, raising roughly $1.6 billion. Compare that to 2021, when roughly 99 companies went public and pulled in $15.6 billion. The door is open, but only for the most polished guests.
The Two-Speed Market
What we're really looking at is a biotech market split into haves and have-nots.
On one side: companies with late-stage clinical data, clear paths to approval, or the magic letters "AI" in their pitch deck. Kailera Therapeutics raised $600 million in the second-largest U.S. biotech round of 2025, backed by Phase 3 obesity data. Eikon Therapeutics pulled in $350.7 million. Xaira Therapeutics closed a billion-dollar-plus launch megaround for AI-driven drug design. These companies aren't extending old rounds; they're commanding premium new ones.
On the other side: earlier-stage companies with platform stories, preclinical programs, or valuations anchored to a market that no longer exists. These are the ones quietly reopening their Series A or B, bringing in an extra $40 million here, $50 million there, and carefully avoiding the words "down round" in any communication.
That gap is pushing traditional discovery-stage companies further into extension territory.
The Hidden Cost of Playing It Safe
Extensions aren't free, even if they look clean on paper. They come with subtle costs that compound over time.
First, there's the signaling problem. A small extension to oversubscribe a hot round? That looks great. A large extension with no new outside investors and flat terms? Sophisticated observers read that as: "nobody new was willing to price this company higher." The label matters less than the substance.
Second, extensions are usually led by existing investors, which means the same people keep writing checks to the same companies. That's fine for now, but it creates a closed loop. Without fresh outside validation, it gets harder to attract new capital down the road. It's like only getting compliments from your mom; eventually you need someone else to confirm you're doing okay.
Third, the can doesn't stop rolling just because you kicked it. Many companies using extensions still need to face a real valuation event eventually, whether that's an IPO, an M&A deal, or a proper new round. Advisory firms describe 2025 as the year of the "biotech reset," with capital returning but loaded with conditions: milestone-based tranches, royalty structures, and tougher investor protections.
What Happens Next
Analysts describe the current cycle as being somewhere around the "sixth inning" of recovery. The public markets are humming. M&A is robust. The IPO window should widen further in 2026. All of that should gradually ease pressure on private valuations.
But "gradually" is doing a lot of heavy lifting in that sentence. The reality is that many 2020-2021 vintage companies still haven't reconciled their old valuations with current market conditions. Some will eventually raise proper up-rounds on the strength of great data. Others will quietly accept down rounds, restructure, or get acquired at prices that make their early investors wince.
For now, extensions are the duct tape holding a lot of cap tables together. They're practical, they're rational, and they buy time for companies to generate the data that justifies a real valuation. But they're also a reminder that in biotech's private markets, the pain from the last bubble hasn't fully healed. It's just been repackaged with a friendlier label.
Clinical & Regulatory
4 min read
The First Pill That Stops COVID Before It Starts
The FDA just approved the first oral antiviral that prevents COVID after exposure, not just treats it. Shionogi's Xocova cut symptomatic infection by 67% in a pivotal trial, filling a gap that's been wide open since Omicron killed off the antibody options.
